GRANOCYTE (lenograstim)
Indication
GRANOCYTE is indicated in adults, adolescents and children aged older than 2 years for the:1-4
Reduction of the duration of neutropenia in patients (with non myeloid malignancy) undergoing myeloablative therapy followed by bone marrow transplantation (BMT) and considered to be at increased risk of prolonged severe neutropenia.
Reduction of the duration of severe neutropenia and its associated complications in patients undergoing established cytotoxic therapy associated with a significant incidence of febrile neutropenia.
Mobilisation of peripheral blood progenitor cells (PBPCs), for patients as well as healthy donors.
GRANOCYTE belongs to a group of medicines called cytokines.1
GRANOCYTE works by helping the body to make more white blood cells which fight infection.
GRANOCYTE is used in patients:
-
After cancer treatment if the level of white blood cells is low resulting in neutropenia.
-
When an increase in white blood cells is required before stem cell mobilisation.
-
Following a bone marrow or stem cell transplant to assist in speeding up the recovery of white blood cells.
-
GRANOCYTE is also licensed to allow healthy donors to donate their stem cells to a suitable recipient.
For full details and a summary of the adverse events please refer to:
Summary of Product Characteristics
→ GRANOCYTE 13.4 million IU/mL, powder and solvent for solution for injection/infusion
→ GRANOCYTE 33.6 million IU/mL, powder and solvent for solution for injection/infusion
→ Granocyte Patient Information Leaflet
Chugai Medical Information: Telephone +44 (0)208 987 5600 or
[email protected]
GRANOCYTE® (Lenograstim [rHuG-CSF])
List price:
Granocyte (Lenograstim 13.4 MIU) Drug tariff price £40.11 per pre-filled syringe.
Granocyte (Lenograstim 33.6 MIU) Drug tariff price £62.54 per pre-filled syringe.
Please check regional & CMU tenders for current NHS prices
Marketing Authorisation:
Marketing Authorisation numbers
PL 12185/0002
PL 12185/0005 (Water for injections in
pre-filled syringe)
Legal classification: POM
Granocyte patient support resources
Information for patients
GRANOCYTE works by helping the body to make more white blood cells which fight infection.
Keep up to date with our innovative medicines and to make sure you are the first to hear more about future resources.
You can also follow Chugai Pharma on LinkedIn
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Chugai Pharma UK Ltd at [email protected] or Tel: +44 (0) 208 987 5600
References
- GRANOCYTE 13 million IU/mL, powder and solvent for solution for injection/infusion, Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/1577/smpc
- GRANOCYTE 13 million IU/mL, powder and solvent for solution for injection/infusion in a pre-filled syringe, Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/7808/smpc
- GRANOCYTE 34 million IU/mL, powder and solvent for solution for injection/infusion, Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/7807/smpc
- GRANOCYTE 34 million IU/mL, powder and solvent for solution for injection/infusion in a pre-filled syringe, Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/7806/smpc
BMT, bone marrow transplantation; IU, international units; PBPCs, peripheral blood progenitor cells; rHuG-CSF, recombinant human granulocyte colony stimulating factor.
C-GB-0000808 | April 2023
